TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00464334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISCOMATRIX™
Description: ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISCOMATRIX™
Description: ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISCOMATRIX™
Description: ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo to V950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo to V950
Study: NCT03006510

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycemia prediction alert
Description: In real time, for a patient with a glucose \<90 mg/d, using a hypoglycemia prediction model that takes into account patient weight, renal function, eating and insulin dosing a risk score is produced.~If the Risk score is \>35, then the patient is determined to be at risk for hypoglycemia in the next 72 hours.~If a patient is determined to be at risk for hypoglycemia, the following will occur:~Alert will be generated and sent via careweb a pager alert system that sends the alert specifically to the current oncall provider The alert also points the provider to the EMR order section where a formal more detailed alert gives recommendationsd for changes in insulin dosing to potentially prevent hypoglycemia.
Study: NCT02393729

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological assessment
Description: The neuropsychological assessment will include an assessment of:~* Intellectual ability~* Laterality~* Reading Skills~* Motor skills~* Oral Language~* Attention~* Child's behaviour

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological assessment
Description: The neuropsychological assessment will include an assessment of:~* Intellectual ability~* Laterality~* Reading Skills~* Motor skills~* Oral Language~* Attention~* Child's behaviour

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological assessment
Description: The neuropsychological assessment will include an assessment of:~* Intellectual ability~* Laterality~* Reading Skills~* Motor skills~* Oral Language~* Attention~* Child's behaviour

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological assessment
Description: The neuropsychological assessment will include an assessment of:~* Intellectual ability~* Laterality~* Reading Skills~* Motor skills~* Oral Language~* Attention~* Child's behaviour

Intervention type: OTHER
Group type: OTHER
Intervention: MRI Study
Description: It will include a first session of about an hour outside MRI for familiarization with the environment of the MRI. The MRI will then be made after a break of 15 minutes~* Morphological time: this time include the initial acquisition of a sequence of anatomical 3D T1-weighted high-resolution contiguous axial slices and the imaging of diffusion tensor.~* Functional time: The experimental paradigm is a paradigm as a block with alternating phase of motor and rest conditions. The two motor tasks are: a Learning motor sequence or motor sequence task and Automated motor sequence or AT (automated task).
Study: NCT03620864

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Control Exercises
Description: Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling.
Study: NCT02393729

Intervention type: OTHER
Group type: OTHER
Intervention: MRI Study
Description: It will include a first session of about an hour outside MRI for familiarization with the environment of the MRI. The MRI will then be made after a break of 15 minutes~* Morphological time: this time include the initial acquisition of a sequence of anatomical 3D T1-weighted high-resolution contiguous axial slices and the imaging of diffusion tensor.~* Functional time: The experimental paradigm is a paradigm as a block with alternating phase of motor and rest conditions. The two motor tasks are: a Learning motor sequence or motor sequence task and Automated motor sequence or AT (automated task).

Intervention type: OTHER
Group type: OTHER
Intervention: MRI Study
Description: It will include a first session of about an hour outside MRI for familiarization with the environment of the MRI. The MRI will then be made after a break of 15 minutes~* Morphological time: this time include the initial acquisition of a sequence of anatomical 3D T1-weighted high-resolution contiguous axial slices and the imaging of diffusion tensor.~* Functional time: The experimental paradigm is a paradigm as a block with alternating phase of motor and rest conditions. The two motor tasks are: a Learning motor sequence or motor sequence task and Automated motor sequence or AT (automated task).

Intervention type: OTHER
Group type: OTHER
Intervention: MRI Study
Description: It will include a first session of about an hour outside MRI for familiarization with the environment of the MRI. The MRI will then be made after a break of 15 minutes~* Morphological time: this time include the initial acquisition of a sequence of anatomical 3D T1-weighted high-resolution contiguous axial slices and the imaging of diffusion tensor.~* Functional time: The experimental paradigm is a paradigm as a block with alternating phase of motor and rest conditions. The two motor tasks are: a Learning motor sequence or motor sequence task and Automated motor sequence or AT (automated task).
Study: NCT02182687

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Trans-Arterial Chemoembolization (TACE)
Description: First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation.

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubin
Description: This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
Study: NCT02154386

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ridge preservation using DFDBA
Description: tooth extraction followed by ridge preservation grafting using DFDBA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ridge preservation using DFDBA
Description: tooth extraction followed by ridge preservation grafting using DFDBA
Study: NCT03002155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EnhanceFitness community exercise program
Description: Level I EnhanceFitness class is a seated fitness class that includes warm up, aerobics, cool down, balance training, strength training, and stretching.
Study: NCT03183193

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control diet
Description: The participants follow a conventional and balanced distribution of macronutrients (30% fat, 15% protein, 55% carbohydrates), adequate fiber (25-30 g/day) and dietary cholesterol (\<250 mg/day) intake according to AHA guidelines. This strategy was included within a personalized energy-restricted diet (-30% individual needs) under healthy lifestyle advice in order to achieve the objectives of AASLD (loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FLiO diet
Description: The participants follow a strategy based on a distribution of macronutrients 30-35% lipid (extra virgin olive oil and fatty acids Ω3 in detriment of saturated, trans and cholesterol)/ protein 25% (vegetable against animal)/carbohydrates 40-45% (low glycaemic index, fiber 30-35 g/day); high adherence to the Mediterranean diet and natural antioxidants; meal frequency of 7 meals/day; size/composition of the ration suitable for each moment; including traditional foods with no additional economic cost that will allow diet adherence without abandonment; avoid inappropriate mealtimes and the eating manners as the eating rate. The participants are instructed to follow this strategy within a personalized energy-restricted diet (-30%) and under healthy lifestyle advice to achieve AASLD objectives.
Study: NCT04261673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompressive Craniectomy
Description: A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. The bone flap should not be replaced at the end of the operation. DC has an advantage in controlling brain swelling, but patient is necessary to have another operation of cranioplasty to reconstruct the skull in the future.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniotomy
Description: A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. However, the bone flap must be replaced and fixed with fixation system (plates and screws). The patient will not need an additional operation to rebuild the skull in the future. But undisciplinable brain swelling and increased intracranial pressure may happen in some patients, and additional decompressive craniectomy is recommended in these cases.
Study: NCT03837470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Sodium Chloride
Description: Intravenous infusion of 0.25ml/kg/min of 0.9% sodium chloride intravenously for a total of 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Description: Bolus intravenous injection of 40 mg furosemide
Study: NCT02705651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin-Analog
Description: A long-acting somatostatin-analog will be applied.
Study: NCT00520364

Intervention type: OTHER
Intervention: Observation of IVF outcomes in relation to chemo history and AMH
Description: Women undergoing IVF with or without history of chemotherapy, AMH levels compared

Intervention type: OTHER
Intervention: Observation of IVF outcomes in relation to chemo history and AMH
Description: Women undergoing IVF with or without history of chemotherapy, AMH levels compared
Study: NCT02111642

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Online risk calculator
Description: A new online risk calculator tool has been developed to predict a woman's individual risk of developing de novo stress urinary incontinence after prolapse surgery. This validated tool has been shown to outperform preoperative prolapse reduction stress testing results and expert predictions when providing risk assessment of de novo stress urinary incontinence after vaginal prolapse surgery. After inputting individual patient characteristics, including patient age, body mass index, number of vaginal deliveries, presence or absence of urgency urinary incontinence and diabetes, and prolapse reduction stress testing results if available, this tool calculates the theoretical risk of postoperative de novo stress urinary incontinence both with and without an anti-incontinence procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online risk calculator
Description: A new online risk calculator tool has been developed to predict a woman's individual risk of developing de novo stress urinary incontinence after prolapse surgery. This validated tool has been shown to outperform preoperative prolapse reduction stress testing results and expert predictions when providing risk assessment of de novo stress urinary incontinence after vaginal prolapse surgery. After inputting individual patient characteristics, including patient age, body mass index, number of vaginal deliveries, presence or absence of urgency urinary incontinence and diabetes, and prolapse reduction stress testing results if available, this tool calculates the theoretical risk of postoperative de novo stress urinary incontinence both with and without an anti-incontinence procedure.
Study: NCT03836391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Nudge is a smartphone-app-based micro-randomized trial that tests the effect of 7 intervention message types based on behavior change techniques on daily goal attainment. Participants have three daily goals: weigh daily, red foods goal, and active minutes goal.
Study: NCT03424252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: Cystic Fibrosis Transmembrane Regulator (CFTR) corrector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: Cystic Fibrosis Transmembrane Regulator (CFTR) corrector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: Cystic Fibrosis Transmembrane Regulator (CFTR) corrector
Study: NCT03620864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Control Exercise Plus Neurodynamic Intervention
Description: Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling. In addition, participants allocated to the neurodynamic group will also receive a nerve neurodynamic slider intervention targeting the main trunk of the sciatic nerve of the affected side during al treatment sessions (n=8).
Study: NCT03540836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant (3x100 mg softgel capsules)
Description: A single relacorilant 300mg dose (3x100 mg softgel capsules) will be given once on Day 1 of one of three treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant (3x100 mg hard-shell capsules)
Description: A single relacorilant 300mg dose (3x100 mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant (6x50mg hard-shell capsules)
Description: A single relacorilant 300mg dose (6x50mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
Study: NCT03424252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: Cystic Fibrosis Transmembrane Regulator (CFTR) corrector
Study: NCT03900403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnut Intake
Description: 40g of daily walnut intake for 12 weeks
Study: NCT01073332

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine antioxidant supplements
Description: The proprietary supplement Niteworks® was manufactured by Herbalife International Inc. (Century City, California, USA). Each serving contained 5.2g L-arginine in a proprietary blend with L-citrulline, 500mg ascorbic acid, 400IU vitamin E, 400ug folic acid, 300mg L-taurine, and 10mg alpha lipoic acid in a lemon-flavored powder form. One serving of supplement powder was mixed with 8 oz of water, administered at bedtime based on the rationale that nitric oxide levels are lowest during sleep due to inactivity, lack of food and low blood pressure.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
Study: NCT01323426

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periurethral injection
Description: Periurethral injection of autologous muscle fibers
Study: NCT00549172

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative (partial arthroscopy)
Description: Partial arthroscopic resection of degenerative rupture of the medial meniscus
Study: NCT03218501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SK-1405 low dose
Description: SK-1405 low dose is to be administered orally once daily for 2 weeks
Study: NCT00549172

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conservative (diagnostic arthroscopy)
Description: Diagnostic arthroscopy
Study: NCT00910793

Intervention type: DRUG
Group type: OTHER
Intervention: Inuvair
Description: 6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
Study: NCT03757208

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carbohydrate rich drink
Description: The carbohydrate rich drink (CHD) group received oral carbohydrate (200 ml) 2-3 h before surgery,
Study: NCT03464656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fairhaven Pro for men
Description: Fairhaven Pro for men~The antioxidant formula (Fairhaven Health) contains:~* B12 (1000 mcg)~* Zinc (30 mg)~* Selenium (140 mcg)~* Arginine (350 mg)~* L-carnitine tartrate (2000 mg) , providing 1,340 mg of L-carnitine~* CoQ10 (200 mg)~* Vitamin C (120 mg) and Vitamin E (200 IU)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Semen analysis
Description: Full semen analysis according to WHO semen laboratory manual 5th edition will be done pre and 3 months post-treatment.~After complete liquefaction, each sample was evaluated for both macroscopic parameters such as color, pH, ejaculate volume, age of the sample and viscosity. An aliquot of the sample was examined for sperm concentration, total sperm count, total and progressive motility and sperm morphology using the WHO fifth edition guidelines (WHO, 2010). Semen analysis was done manually using a hemocytometer. Sperm motility was assessed and categorized as progressive or non-progressive. Morphology was assessed by a single experienced technician using the Diff-Quik staining protocol. Kruger's strict criteria were used for morphology assessment with 4% normal morphology as a cut-off (WHO, 2010).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sperm DNA fragmentation
Description: Sperm DNA fragmentation was evaluated using the Halosperm kit from Halotech DNA, S.L. (Madrid, Spain) as per manufacturer instructions. The method is based on the sperm chromatin dispersion test (Fernández et al., 2003). A minimum of 500 spermatozoa were scored and reported as percentage of sperm with spermatozoa with fragmented DNA. Normal value is measure at a cut-off value of more than 30%

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static Oxidation reduction potential in semen
Description: Oxidative stress was assessed by measuring the static oxidation-reduction potential (sORP) of neat liquefied semen samples using the MiOXSYSTM System (Aytu Bioscience, Inc., Englewood, USA). This is a galvanostatic measure of the electron transfer from reductants (antioxidants) to oxidants under a steady low voltage reducing current. Thus, providing an aggregate measure of all current oxidant activity and antioxidant activity in a sample. Higher sORP values (millivolts, mV) indicate a higher oxidant activity relative to the antioxidant activity and therefore greater state of oxidative stress.
Study: NCT00829907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: Single dose as a capsule, oral administration
Study: NCT00814775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fastrach Laryngeal Mask
Description: Intubation of difficult airway using Fastrach Laryngeal Mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CTrach Laryngeal Mask
Description: CTrach Laryngeal Mask intubation
Study: NCT05422807

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BFST for Teens with Type 2 Diabetes
Description: 12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
Study: NCT03579784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 150mg bid on D1-28 Every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1.5 g iv on D1 Every 4 weeks
Study: NCT03358719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given intracutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given SC
Study: NCT02595723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin 200 mg capsule
Description: Phenytoin oral capsule was initiated on Day 1 and administered at 200 mg twice/day for four consecutive days (Days 1 - 4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol 800 mg liquid
Description: Liquid megestrol 800 mg/was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol 800 mg liquid
Description: Liquid megestrol 800 mg/was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).
Study: NCT03218501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is to be administered orally once daily for 2 weeks
Study: NCT01008644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: The subjects will drink tap water for 2 hours, volume calculated according to weight: 20ml/kg/hour.
Study: NCT02595723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin-matched Placebo capsule
Description: Phenytoin-matched oral Placebo capsule was initiated on Day 1 and administered for four consecutive days (Days 1 - 4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin-matched Placebo capsule
Description: Phenytoin-matched oral Placebo capsule was initiated on Day 1 and administered for four consecutive days (Days 1 - 4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol-matched liquid Placebo
Description: Megestrol-matched liquid placebo was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).